HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Zacks Education
Visit Zacks'
Education section for investing guides and other free resources to make you a better investor.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

CVS Caremark Beats by a Penny

By: Zacks Equity Research
November 05, 2009 | Comments: 0
Recommended this article (2)
CVS
Print    Share

CVS Caremark’s (CVS - Analyst Report) third-quarter earnings came in at 65 cents, a cent above the Zacks Consensus Estimate and higher than 60 cents reported in the year ago period. Revenues increased 18.2% year over year to $24.6 billion primarily due to robust growth of both segments - pharmacy services and retail pharmacy. However, gross margin declined to 20.3% in the reported quarter compared to 21.1% in the year ago period.

We are pleased to see the robust performance of the pharmacy services segment during the reported quarter. Revenues increased 23.4% to $13 billion. Revenue growth would have been higher at 27.2% but for the recent generic introductions. While pharmacy netwok claims processed during the quarter increased 9% year over year to 146.5 million due to the addition of RxAmerica claims and new client wins, offset partially by a reduction in claims due to the termination of two large contracts (effective beginning of 2009), mail choice claims increased 11.4% to 16.4 million.

The performance of the retail pharmacy business is also quite commendable. Revenues increased 17.9% to $13.6 billion in the third quarter. Despite industry wide pricing pressure in the pharmacy business, results over the past several quarters have demonstrated strong sales trends with comparable same-store sales growing at solid rates.

Same-store sales increased 5.7% over the prior-year period. While pharmacy same store sales rose 8%, front end same store sales increased 0.8%. Pharmacy same store sales were negatively impacted by 380 basis points due to recent generic introductions whereas Maintenance Choice program had a positive impact of 250 basis points. Generic dispensing rate increased both in the pharmacy services and retail segment by 320 basis points to 68.3% and 210 basis points to 70.1%, respectively.

Based on the strong third quarter performance, CVS Caremark increased the lower end of its guidance for 2009. The company now expects earnings per share in the range of $2.61-$2.64, up from the previous guidance of $2.59-$2.64.


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Free Stock Analysis From Zacks
  Includes Zacks Long-Term Recommendation and Target Price
Read/Post Comments (0) | Recommended this article (2)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Feb 10, 2010 08:45 am ET
DJIA 10058.64  0.00 0.00%
NASD 2150.87  0.00 0.00%
S&P 500 1070.52  0.00 0.00%